Support Overview

Discover an entire system of support, because care starts with you.

 

Contact Us

 

BDVeritor Support Header

Point-of-care training and support

Content Card Image

Videos & Documents

 

Easy-to-access educational resources to support you throughout the process.

Content Card Image

FAQ

 

Answers to the most common questions about the BD Veritor™ Plus System testing experience.

Designed with You in Mind

Content Card Image

BD Veritor™ System

Learn about Professional Care testing with the BD Veritor™ System.

Content Card Image

BD Veritor™ System Overview Brochure

Learn more about the BD Veritor™ Plus System.

Need more support?

 

 

For additional training, equipment servicing, and more, contact our Customer Success team.

BD Veritor™ Plus System Education & Training

Discover the tools that enable you to streamline the point-of-care experience for those you serve.

FAQ

Please visit our FAQ for more information on our testing capabilities and our products.

RSV=respiratory syncytial virus; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.

*In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID 19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.